Dr. Halmos is the Director of Thoracic Oncology at Montefiore Einstein in New York City. He is among the most engaging and engaged key opinion leaders in lung cancer social media.  His tweets are an interesting combination of clinical trial results and memes. He is seen as a leader in both research and social media, often taking the podium to share his teachings with his peers in Lung Cancer Treatment. 

Enthusiasm for Oncological Advancements

Dr. Halmos exhibits a palpable excitement for recent advancements in oncology, underlined by his enthusiasm for clinical trials and groundbreaking research. His tweet referencing the #ESMO23 conference illustrates this perfectly: > "But if you are dizzy like myself about all the new information- ALINA, MARiPOSA, PAPILLON, TROPION, AEGEAN, KN671, CM77- you name it. No worries- just join us on Nov 11 for NY Lung and our expert panels will put the data into context for us!" (Link)

Here, Dr. Halmos acknowledges the overwhelming pace of new information but underscores his dedication to contextualizing and understanding it better. This sentiment is further strengthened by his response to a tweet about bispecific antibodies, where humor and excitement intersect: 

Advocacy for Patient-Centric Treatments

A core aspect of Dr. Halmos' online activity is his enthusiasm for new therapies, combined with a meme or two... For instance, in discussing the ADAURA study's impressive results, he combines statistical insight with a touch of humor toward his colleagues: > "Undisputed + outcome of the ADAURA study is that it robustly extended the OS of the great and wild West/Pennell debate- amazing 3 years+ OS already! Highly sign w 0 cross-over the debate fence so far!😉 DFS (debate free survival) is not reached yet!" (Link)

This blend of data-centric focus with lighter commentary makes his Twitter presence both informative and engaging.

Skepticism and Critical Analysis

While Dr. Halmos exhibits a generally positive outlook, he doesn't shy away from critical analysis. For instance, his tweet about the challenges in deploying Guardant Shield liquid biopsy tests highlights a cautious and measured skepticism: > "So should we all Guardant Shield? Point of colonoscopy is to find polyps+ remove them to prevent cancer- finding cancer by ctDNA is no success.. Considering RW use: if pretest prob of polyp average 11%- +test changes it to 13, neg reduces it to 10.5% so i’d say: Guarda-not yet!" (Link)

In this post, he carefully breaks down the predictive value estimates and emphasizes practical cancer prevention strategies over novel, yet unproven, methods.

Celebrating Collaborative Efforts

Dr. Halmos frequently acknowledges the efforts of his colleagues and the value of teamwork in healthcare. Celebrating achievements and thanking those who contribute to impactful studies is a recurring theme: > 

His recognition of team efforts and collaborative triumphs adds to his persona of a dedicated and appreciative professional.

Conclusion

Dr. Balazs Halmos exemplifies an engaged and insightful oncologist on social media, blending professional rigor with a personable touch. His tweets range from celebrating new treatment breakthroughs and critical analysis of current methodologies to advocating for the best possible patient care and acknowledging his colleagues' contributions. As seen through his posts, Dr. Halmos not only stays current with medical advancements but also brings an influential and balanced voice to the digital healthcare community.